Skip to content

Biosimilars, Biologics, FDA Policy and Approvals, Clinical Trials, and Specialty Pharmacy

  • Home
    • Home
  • About BR&R
  • Biosimilar Approval Status
  • BR&R Product Profiles
    • Abrilada
    • Amjevita
    • Avasola
    • Byooviz
    • Cyltezo
    • Erelzi
    • Eticovo
    • Fulphila
    • Hadlima
    • Herzuma
    • Hulio
    • Hyrimoz
    • Inflectra
    • Kanjinti
    • Mvasi
    • Nivestym
    • Nyvepria
    • Ogivri
    • Ontruzant
    • Renflexis
    • Retacrit
    • Riabni
    • Ruxience
    • Semglee
    • Trazimera
    • Truxima
    • Udenyca
    • Yusimry
    • Zarxio
    • Ziextenzo
    • Zirabev
  • Contact Us
  • The 2023 Biosimilars Market Report
  • $0.00 0 items

Cart

Your cart is currently empty.

Return to shop

SM Health Comm

Recent Posts

  • More Confirmation that Payers Will Cover Beyond the Skinny Label May 16, 2022
  • Competition Squeezes Coherus’ Pegfilgrastim Revenues: Big Expectations for its On-Body Injector May 11, 2022
  • Will a Pharmacy Benefit Design Someday Include a Biosimilar Tier? Not Likely, and Here’s Why May 3, 2022
  • And Then There Were None: Celltrion Signs AbbVie Licensing Deal for Its Adalimumab Biosimilar CT-P17 April 28, 2022
  • Preliminary Phase 3 Study Data Looking Good for Amgen’s Ustekinumab Biosimilar April 20, 2022
  • Amneal Scores FDA Approval of Alymsys®, a Biosimilar of Bevacizumab April 15, 2022
  • A Profile on Lesser-Known Player in the Biosimilar Space: Prestige Biopharma April 8, 2022
  • Biosimilar Bytes April 7, 2022
  • A Conversation With Sarah Ikenberry and Laura Pincock, Food and Drug Administration on Biosimilar Education in Health Sciences Schools March 21, 2022
  • It Will Be Difficult to Move Away from Phase 3 Studies for Biosimilar Approvals March 17, 2022

Recent Comments

More Confirmation th… on Do Skinny Labels for Biosimila…
Competition Squeezes… on Progress on Coherus’ Pegfilgra…
Will a Pharmacy Bene… on Patient Cost-Sharing “Advantag…
Will a Pharmacy Bene… on What Do Patients Want to Know…
rbtoneill on Insulin Wars: Biosimilar Susta…

Archives

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Top Posts & Pages

  • Biosimilar Approval Status
  • Ustekinumab Biosimilars Update
  • Denosumab Biosimilar Competitors Gathering Data for February 2025 Launch
  • More Confirmation that Payers Will Cover Beyond the Skinny Label
  • The Interesting Scenario for a Tysabri® Biosimilar for Multiple Sclerosis
  • The Evolution of the Biosimilars Market
  • About BR&R
  • Who Are the Key Aflibercept Biosimilar Players to Watch?
  • Abrilada
  • Will a Pharmacy Benefit Design Someday Include a Biosimilar Tier? Not Likely, and Here’s Why
Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookie Policy

Follow Us

  • Twitter
  • LinkedIn
  • Home
  • About BR&R
  • Biosimilar Approval Status
  • Contact Us
  • Terms and Conditions

Copyright

Copyright 2013-2022 by SM Health Communications. All Rights Reserved

Powered by WordPress.com.